"N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide"@en . "Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness."@en . . . . . . . "Humans and other mammals"@en . . . . . . . . "Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Sandip Vasant Chikhalikar, Maruti Ghagare, \"Process for the synthesis of naratriptan.\" U.S. Patent US20120220778, issued August 30, 2012."@en . " "@en . . . . . . . . . . . . "investigational"@en . . . "# Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12463278 # Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16389295 # Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15320857"@en . . "approved"@en . . "Naratriptan"@en . "* 6.6 mL/min/kg"@en . . . "For the acute treatment of migraine attacks with or without aura in adults."@en . "N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide"@en . . . "5-8 hours"@en . . . . . . . "Take without regard to meals."@en . . . . "28%-31% (over the concentration range of 50 to 1000 ng/mL)"@en . . . . "121679-13-8"@en . . . . "Naratriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist."@en . . . . "* 170 L"@en . . . "Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism."@en . . . . . . . . . . . . "Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack."@en . . . . . . "Naratriptanum"@en . .